Fig. 1: DNA/EP delivery of BG505.MD39 can enable in vivo expression of conformationally complex NLT.

a SEC trace of lectin-column purified BG505.MD39 that has been sequence optimized for in vivo expression. b Antigenic profile of sequence optimized BG505.MD39 in terms of ELISA binding to V2-apex directed bNAb PGT145 and v3-directed non-nAb 3074. c nsEM image of SEC purified sequence optimized BG505.MD39. d Coomassie staining for the migrations of the purified in vitro expressed BG505.MD39 and BG505 gp120 protein standards on 3–12% Bis-Tris NATIVE PAGE gels. e 2G12-based western analysis to compare the migrations of the in vivo produced BG505.MD39 in muscle homogenates from mice treated with DNA-encoded BG505.MD39 (harvested 4 d.p.i) to those of in vitro produced BG505.MD39 and BG505 gp120 on a 3–12% Bis-Tris NATIVE PAGE gel. f Immunofluorescence analyses of muscle sections from mice treated intramuscularly with DNA-encoded BG505.MD39 or BG505.gp120.foldon (harvested 7 d.p.i) in terms of binding to bNAb PGT145 or non-nAb 3074. g Normalized area under the curve (ratio of in vivo produced pMD39 binding versus pGP120-foldon binding) for binding to HIV bNAbs and non-NAbs. For c, d, e, and f, the experiments were repeated twice.